170 related articles for article (PubMed ID: 23580409)
1. In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer.
Goetz M; Hoetker MS; Diken M; Galle PR; Kiesslich R
Endoscopy; 2013 Jun; 45(6):469-77. PubMed ID: 23580409
[TBL] [Abstract][Full Text] [Related]
2. In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor.
Goetz M; Ziebart A; Foersch S; Vieth M; Waldner MJ; Delaney P; Galle PR; Neurath MF; Kiesslich R
Gastroenterology; 2010 Feb; 138(2):435-46. PubMed ID: 19852961
[TBL] [Abstract][Full Text] [Related]
3. Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptor.
Hoetker MS; Kiesslich R; Diken M; Moehler M; Galle PR; Li Y; Goetz M
Gastrointest Endosc; 2012 Sep; 76(3):612-20. PubMed ID: 22771099
[TBL] [Abstract][Full Text] [Related]
4. In vivo molecular imaging of epidermal growth factor receptor in patients with colorectal neoplasia using confocal laser endomicroscopy.
Liu J; Zuo X; Li C; Yu T; Gu X; Zhou C; Li Z; Goetz M; Kiesslich R; Li Y
Cancer Lett; 2013 Apr; 330(2):200-7. PubMed ID: 23220286
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
6. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
8. In vivo molecular imaging of gastric cancer by targeting MG7 antigen with confocal laser endomicroscopy.
Li Z; Zuo XL; Li CQ; Zhou CJ; Liu J; Goetz M; Kiesslich R; Wu KC; Fan DM; Li YQ
Endoscopy; 2013; 45(2):79-85. PubMed ID: 23364839
[TBL] [Abstract][Full Text] [Related]
9. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
Mutsaers AJ; Francia G; Man S; Lee CR; Ebos JM; Wu Y; Witte L; Berry S; Moore M; Kerbel RS
Clin Cancer Res; 2009 Apr; 15(7):2397-405. PubMed ID: 19276250
[TBL] [Abstract][Full Text] [Related]
11. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
12. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
14. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number.
Italiano A; Follana P; Caroli FX; Badetti JL; Benchimol D; Garnier G; Gugenheim J; Haudebourg J; Keslair F; Lesbats G; Lledo G; Roussel JF; Pedeutour F; François E
Ann Surg Oncol; 2008 Feb; 15(2):649-54. PubMed ID: 17987340
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
Rosa R; Marciano R; Malapelle U; Formisano L; Nappi L; D'Amato C; D'Amato V; Damiano V; Marfè G; Del Vecchio S; Zannetti A; Greco A; De Stefano A; Carlomagno C; Veneziani BM; Troncone G; De Placido S; Bianco R
Clin Cancer Res; 2013 Jan; 19(1):138-47. PubMed ID: 23166225
[TBL] [Abstract][Full Text] [Related]
18. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
19. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]